3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
13
Gynecologic
11
Gastrointestinal
10
Breast
7
Head & Neck
3
Genitourinary
2
Other solid neoplasm
1
Endocrine
1
Dermatologic
1
Conditions
Thyroid Carcinoma, Anaplastic
10
Thyroid Neoplasms
7
Lung Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Neuroendocrine
3
Small Cell Lung Carcinoma
2
Neuroendocrine Tumors
2
Carcinoma, Ovarian Epithelial
2
Thyroid Cancer, Papillary
1
Squamous Cell Carcinoma of Head and Neck
1
Salivary Gland Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Melanoma
1
Lethal Congenital Contracture Syndrome 2
1
Hypopharyngeal Neoplasms
1
Esthesioneuroblastoma, Olfactory
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma, Medullary
1
Carcinoma, Large Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
1
osimertinib
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Paclitaxel
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Paclitaxel
×
Endocrine
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled